Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.

European journal of preventive cardiology - 1 Nov 2017

Baragetti Andrea, Balzarotti Gloria, Grigore Liliana, Pellegatta Fabio, Guerrini Uliano, Pisano Giuseppina, Fracanzani Anna L, Fargion Silvia, Norata Giuseppe D, Catapano Alberico L

Abstract excerpt

Background Proprotein convertase subtilisin kexin type 9 (PCSK9) regulates low-density lipoprotein and very low-density lipoprotein receptor expression in several tissues. Here we evaluated whether PCSK9 may modulate the handling of triglycerides in the liver and peripheral tissues. Methods Subjects from the PLIC cohort were genotyped for the loss-of-function PCSK9 R46L variant and characterized for clinical and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipose Tissue
Share to Adiposity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Body Mass Index

Share to Cholesterol, LDL

Share to Loss of Function Mutation

Share to Mice, Knockout

Share to Proprotein Convertase 9

Source

Identifiers

PMID: 28758421
DOI: 10.1177/2047487317724342

Genes

PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.PMID 28758421Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read ↗

The PCSK9 decade.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency.Semantic proximity Read ↗

Molecular biology of PCSK9: its role in LDL metabolism.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.Semantic proximity Read ↗

PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarkerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.